Multiple sensory impairments and their associations with blood-based biomarkers for Alzheimer's disease and related dementias - Project Summary Given the growing burden of Alzheimer’s disease (AD) and related dementias (ADRD) strategies for prediction, early detection, and prevention are needed. Sensory impairments in hearing, vision, and olfaction are common in older adults and are associated with a higher risk of dementia. Furthermore, having multiple sensory (e.g., multisensory) impairments is more strongly associated with dementia than having a single impairment. These associations have important implications in that sensory impairments could aid in the prediction and/or prevention of AD/ADRD. However, there is a critical gap in knowledge as to the extent to which sensory impairments in hearing, vision, olfaction, or multiple senses are associated with AD/ADRD blood-based biomarkers. We have an exciting opportunity to study the relationships between sensory loss and AD/ADRD blood-based biomarkers in the Healthy Brain Initiative (HBI), a newly established cohort of 500 older adults, aged 50+ in South Florida, with in-depth phenotyping. HBI is collecting annual measures of sensory loss (hearing, vision, and olfaction), cognition, and multiple AD/ADRD blood-based biomarkers. HBI collects pure- tone audiometry of hearing loss, self-reported vision impairment, ocular diseases (e.g., cataracts), color vision test (a potential predictor for ADRDs), and a smell identification test. Multiple blood-based biomarkers, including AD-related biomarkers (amyloidß (Aß) 42/40, p-tau181, p-tau217, and p-tau/np-tau) and markers of general neurodegeneration (neurofilament light (NfL), glial fibrillary acidic protein (GFAP) are collected at each visit. We expect up to 3 years of data for preliminary longitudinal analyses. The goal of this study is to examine associations of sensory impairments and AD/ADRD blood-based biomarkers in HBI. We hypothesize that individual sensory impairments will be associated with multiple biomarkers, and that multisensory impairment may be a stronger predictor of AD/ADRD blood-based biomarkers compared to individual impairments. Under Aim 1, we will evaluate the cross-sectional associations between sensory impairments (in hearing, vision, and olfaction) and AD/ADRD blood-based biomarkers. Under Aim 2, we will examine the cross-sectional associations between multisensory impairment and AD/ADRD blood-based biomarkers. In an exploratory Aim 3, we will examine the longitudinal associations between sensory impairments (individual and multiple) and AD/ADRD blood-based biomarkers. This project will help lay the foundation for further longitudinal studies and clarify the biologic mechanisms linking sensory loss to AD/ADRD. Identifying associations between sensory loss and AD/ADRD blood-based biomarkers would also inform the development of risk-stratification and intervention strategies for early detection and prevention of dementia.